GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progenics Pharmaceuticals Inc (FRA:PGP) » Definitions » E10

Progenics Pharmaceuticals (FRA:PGP) E10 : €-0.56 (As of Mar. 2020)


View and export this data going back to 1997. Start your Free Trial

What is Progenics Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Progenics Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2020 was €-0.172. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.56 for the trailing ten years ended in Mar. 2020.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-05-26), Progenics Pharmaceuticals's current stock price is €4.16. Progenics Pharmaceuticals's E10 for the quarter that ended in Mar. 2020 was €-0.56. Progenics Pharmaceuticals's Shiller PE Ratio of today is .


Progenics Pharmaceuticals E10 Historical Data

The historical data trend for Progenics Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progenics Pharmaceuticals E10 Chart

Progenics Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.92 -0.88 -0.65 -0.57 -0.62

Progenics Pharmaceuticals Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.65 -0.61 -0.65 -0.62 -0.56

Competitive Comparison of Progenics Pharmaceuticals's E10

For the Biotechnology subindustry, Progenics Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Progenics Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Progenics Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Progenics Pharmaceuticals's Shiller PE Ratio falls into.



Progenics Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Progenics Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2020 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2020 (Change)*Current CPI (Mar. 2020)
=-0.172/108.9015*108.9015
=-0.172

Current CPI (Mar. 2020) = 108.9015.

Progenics Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201006 -0.384 91.962 -0.455
201009 -0.397 92.162 -0.469
201012 -0.431 92.474 -0.508
201103 -0.492 94.283 -0.568
201106 1.138 95.235 1.301
201109 -0.247 95.727 -0.281
201112 -0.243 95.213 -0.278
201203 -0.295 96.783 -0.332
201206 -0.255 96.819 -0.287
201209 -0.256 97.633 -0.286
201212 0.015 96.871 0.017
201303 -0.170 98.209 -0.189
201306 -0.182 98.518 -0.201
201309 -0.127 98.790 -0.140
201312 -0.095 98.326 -0.105
201403 -0.108 99.695 -0.118
201406 -0.118 100.560 -0.128
201409 0.396 100.428 0.429
201412 -0.146 99.070 -0.160
201503 -0.139 99.621 -0.152
201506 -0.151 100.684 -0.163
201509 -0.125 100.392 -0.136
201512 -0.092 99.792 -0.100
201603 -0.162 100.470 -0.176
201606 -0.071 101.688 -0.076
201609 0.463 101.861 0.495
201612 -0.095 101.863 -0.102
201703 -0.215 102.862 -0.228
201706 -0.214 103.349 -0.225
201709 -0.185 104.136 -0.193
201712 -0.034 104.011 -0.036
201803 -0.154 105.290 -0.159
201806 -0.171 106.317 -0.175
201809 -0.257 106.507 -0.263
201812 -0.149 105.998 -0.153
201903 -0.195 107.251 -0.198
201906 -0.204 108.070 -0.206
201909 -0.200 108.329 -0.201
201912 -0.117 108.420 -0.118
202003 -0.172 108.902 -0.172

Add all the adjusted EPS together and divide 10 will get our e10.


Progenics Pharmaceuticals  (FRA:PGP) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Progenics Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Progenics Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Progenics Pharmaceuticals (FRA:PGP) Business Description

Traded in Other Exchanges
N/A
Address
One World Trade Center, Suite J, 47th Floor, New York, NY, USA, 10007
Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.

Progenics Pharmaceuticals (FRA:PGP) Headlines

From GuruFocus

PGP Statement on SEC Settlement

By sperokesalga sperokesalga 06-16-2023